TrialJournal of hematology & oncology2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
Sven de Vos et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
59 papers cite it
this paperpooled itcites it